Effect of octreotide-deoxycholate hydrophobic ion pairing solid dispersions on intestinal permeability to enhance octreotide absorption via increased lipophilicity and ASBT-mediated transport. (PubMed, Int J Pharm) - Apr 1, 2026 - "FDA-approved oral octreotide capsule Mycapssa® (octreotide, an 8-amino-acid cyclic peptide) shows only 0.7% bioavailability in humans despite permeation enhancers...In vivo, OCT-NaDC HIP solid dispersion achieved a relative oral bioavailability of 11.54% in SD rats versus subcutaneous injection, exceeding OCT-NaDC HIP complexes (6.04%) and the OCT-NaUDC HIP solid dispersion (8.60%). Overall, OCT-NaDC HIP solid dispersion integrates rapid dissolution with bile acid-assisted absorption, offering a practical strategy for oral peptide delivery."
Journal
|
|
Feng Xiao; Hongyu Piao; Meijuan Zou; Xiaohui Zhang
|